TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7510746
Drug: TCR V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCR V beta 5.2(39-59) and V beta 6.1(39-59) peptides at low doses (100 to 300 micrograms)
Study: 1101065
Drug: HBIG (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIG (high concentration of antibodies to surface components of hepatitis B virus, 442 mug per milliliter)
Study: 1101065
Drug: Control human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control human immune globulin preparation
Study: 15561379
Drug: Intra-articular analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular analgesics (short acting anaesthetics)
Study: 11368732
Drug: Salmeterol (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (42 microg twice per day)
Study: 11368732
Drug: Triamcinolone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (400 microg twice per day)
Study: 9164377
Drug: Protocol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol treatment completion
Study: 8706197
Drug: Edrophonium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.25 mg x kg(‐1)
Study: 8706197
Drug: Edrophonium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.5 mg x kg(‐1)
Study: 8706197
Drug: Placebo (0.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.0 mg x kg(‐1) edrophonium)
Study: 17947502
Drug: Long-duration IH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-duration IH (LDIH) protocol: daily 60-min exposures to normobaric 12% O(2)
Study: 17947502
Drug: Short-duration IH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-duration IH (SDIH) protocol: twelve 5-min bouts of 12% O(2), separated by 5-min bouts of room air, daily
Study: 6830410
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (average, 40 mg/day for up to four years)
Study: 6830410
Drug: Adjunctive thioridazine
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive thioridazine hydrochloride (mean, 87 mg/day)
Study: 30609411
Drug: Caralluma fimbriata
Normalized name: CARALLUMA FIMBRIATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caralluma fimbriata extract (CFE) 500 mg b.d. (n = 49)
Study: 30609411
Drug: Placebo 500
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500 mg b.d. (n = 48)
Study: 24123098
Drug: Intensive low-density
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive low-density lipoprotein (LDL)‐lowering therapy with LDL‐apheresis
Study: 17993364
Drug: diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 50 mg twice daily and placebo manipulative therapy
Study: 17993364
Drug: spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: spinal manipulative therapy and placebo drug
Study: 17993364
Drug: diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 50 mg twice daily and spinal manipulative therapy
Study: 11942978
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG therapy (102 patients)
Study: 2406439
Drug: Cefoxitin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin prophylaxis (3 doses of 2g each: initial dose after cord clamping, subsequent doses at 4 and 8 hours)
Study: 28861803
Drug: Electro-acupuncture (EA)
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture (EA) treatment
Study: 17551159
Drug: Control (metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (metformin plus sulfonylurea)
Study: 15167084
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.15 mg/kg b.i.d.
Study: 15167084
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.30 mg/kg b.i.d.
Study: 8169187
Drug: 5.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/kg caffeine
Study: 3477659
Drug: Retinol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinol (15 mg or 50,000 IU), riboflavin (200 mg), and zinc (50 mg)
Study: 28183047
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of an ellagitannin-containing pomegranate extract (PE) daily
Study: 22832034
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole 10 mg (6-11 years)
Study: 22832034
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole 40 mg (12-17 years)
Study: 22832034
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole 0.5 mg/kg (0-1 month)
Study: 22832034
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole (various doses)
Study: 17392726
Drug: Naloxone 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.01 mg/kg
Study: 12065339
Drug: Clarithromycin, 500
Normalized name: Clarithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 500 mg bid for 6 weeks
Study: 9469367
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral granisetron (2 mg)
Study: 9469367
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron (32 mg)
Study: 7648772
Drug: Entacapone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (400 mg single dose)
Study: 2652209
Drug: Systematic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic antibiotic prophylaxis for 48 h with sodium cefuroxim, 1.5 g the first dose and subsequent doses of 750 mg iv
Study: 2652209
Drug: Selective antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective antibiotic prophylaxis based on determination of preoperative gastric pH (pH < 4, no antibiotic prophylaxis; pH > 4, prophylaxis as in group I)
Study: 2652209
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy beginning postoperatively with cefuroxim 750 mg every 78 h for 4 days
Study: 817696
Drug: Clonazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (3 to 6 mg daily) combined with previous antiepileptic drugs
Study: 817696
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with previous antiepileptic drugs
Study: 27119580
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro 200 U/mL (IL200)
Study: 27119580
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro 100 U/mL (IL100)
Study: 17481947
Drug: Optimal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal therapy for advanced chronic heart failure (specific intervention details not provided)
Study: 7880791
Drug: Topical fusidic
Normalized name: fusidate Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fusidic acid gel (Fucithalmic)
Study: 7880791
Drug: Oral oxytetracycline
Normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxytetracycline
Study: 7880791
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fusidic acid gel and oxytetracycline
Study: 2245455
Drug: Nicardipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (20 mg twice a day)
Study: 386974
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg propylthiouracil every two hours (group A)
Study: 386974
Drug: 100 mg,
Normalized name: CoQmax Omega 100 mg, 500 mg-100 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, 100 mg, and 150 mg propylthiouracil at 8 hour intervals (group B)
Study: 23514874
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with sevoflurane and fentanyl, and systemically administered opioids
Study: 19144532
Drug: Ambroxol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (1000 mg/day by intravenous infusion on the day of operation and on the first 3 postoperative days)
Study: 19144532
Drug: Fluid therapy
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid therapy only without ambroxol
Study: 2681508
Drug: Cholestyramine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 12 g b.i.d.
Study: 2681508
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg q.p.m.
Study: 2681508
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Simvastatin + Cholestyramine)
Study: 2681508
Drug: Simvastatin monotherapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin monotherapy after 52 weeks
Study: 28410617
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (2 g/day for 3 months)
Study: 24069844
Drug: Non-surgical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical therapy with EMD
Study: 21739692
Drug: Acupoint catgut-embedding
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut-embedding combined western medicine (ACCWM)
Study: 21739692
Drug: Simple western
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple western medicine (WM)
Study: 16714961
Drug: Brief focal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief focal ultrasound followed by a 5-minute application of a 4% lidocaine topical anesthetic
Study: 11323371
Drug: Diltiazem (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (10 mg)
Study: 9293935
Drug: Intraoperative intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intermittent sequential compression (ISC)
Study: 27199121
Drug: nebivolol (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol (5-20 mg/day)
Study: 27199121
Drug: metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metoprolol succinate (100-300 mg/day)
Study: 25701829
Drug: Nicorandil 10
Normalized name: nicorandil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 10 mg, 2 times a day (n = 27)
Study: 19451137
Drug: COBRA combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA combination therapy (step-down prednisolone, methotrexate, and sulfasalazine)
Study: 19451137
Drug: Sulfasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine (SSZ) monotherapy
Study: 18193385
Drug: Teicoplanin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (800 mg on day 1, then 400 mg/day) + piperacillin/tazobactam + gentamicin
Study: 18193385
Drug: Vancomycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (2 g/day) + meropenem + levofloxacin
Study: 17106142
Drug: Candesartan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4 mg, most frequent dose)
Study: 17106142
Drug: ACEI (lisinopril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (lisinopril, enalapril, trandolapril)
Study: 12612168
Drug: Protein supplements
Normalized name: PROTEIN SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplements with supplemental calcium
Study: 8632120
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate 10 mg
Study: 8632120
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate 25 mg
Study: 8632120
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate 50 mg
Study: 8632120
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate 100 mg
Study: 1600852
Drug: Nilvadipine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (8 mg per day)
Study: 1600852
Drug: Captopril (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75 mg per day)
Study: 2866789
Drug: L-714,465 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-714,465 1% eyedrops
Study: 22456954
Drug: Date palm
Normalized name: date palm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Date palm immunotherapy (IT) for 15 months
Study: 18565853
Drug: Clofarabine plus
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine plus low-dose cytarabine
Study: 15823640
Drug: switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: switching to rosuvastatin 10 mg from atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg
Study: 15823640
Drug: switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: switching to rosuvastatin 20 mg from atorvastatin 20 mg
Study: 15823640
Drug: switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: switching to rosuvastatin 10 mg from atorvastatin 20 mg
Study: 12874270
Drug: Chemotherapy (etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (etoposide plus cisplatin) plus daily radiation therapy (RT)
Study: 12874270
Drug: Chemotherapy (etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (etoposide plus cisplatin) plus split-course radiation therapy (RT) bid
Study: 10381769
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg amphetamine
Study: 9345413
Drug: Chimeric monoclonal
Normalized name: Chimeric monoclonal antibody to mesothelin
DrugBank: Amatuximab (DB12845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric monoclonal anti-CD4 antibodies
Study: 1879990
Drug: Netilmicin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin (5 mg/kg intramuscularly)
Study: 1879990
Drug: Amikacin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (15 mg/kg intramuscularly)
Study: 1879990
Drug: Fosfomycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (3 g per os)
Study: 28657871
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg/day for 3 weeks, then 20 mg/day)
Study: 28657871
Drug: tDCS (30-minute,
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS (30-minute, 2-mA sessions for 15 weekdays, followed by 7 weekly treatments)
Study: 28657871
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral placebo)
Study: 25819170
Drug: Doxapram injection
Normalized name: doxapram Injectable Solution
DrugBank: Doxapram (DB00561)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxapram injection
Study: 20032908
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injections with static night splint
Study: 20032908
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injections without static night splint
Study: 18396651
Drug: CEF-100 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF-100 regimen (epirubicin 100 mg/m2, dl per 21 days for 6 cycles, n =48)
Study: 18396651
Drug: CEF-60 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF-60 regimen (epirubicin 60 mg/m2, dl per 21 days for 6 cycles, n = 50)
Study: 15297048
Drug: HPV18 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV18 L1 VLP vaccine
Study: 28853210
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (as a reference)
Study: 25641199
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl spray (INFS) 400 μg
Study: 17330681
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg) plus methotrexate
Study: 11929342
Drug: Moxifloxacin 400mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 400mg once daily for 7 days
Study: 11929342
Drug: Cephalexin 500mg
Normalized name: CEPHALEXIN 500MG TAB
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 500mg three times daily for 7 days
Study: 30965392
Drug: Satavaptan (vasopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan (vasopressin V2 antagonist)
Study: 28648618
Drug: H-s.c. (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-s.c. (subcutaneous trastuzumab)
Study: 28648618
Drug: H-i.v. (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-i.v. (intravenous trastuzumab)
Study: 17644057
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with rabeprazole 20mg o.d., levofloxacin 500 mg o.d., and amoxycillin 1g b.i.d. (4 tablets/day)
Study: 17644057
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy comprising of rabeprazole 20mg, clarithromycin 500 mg, tinidazole 500 mg plus bovine lactoferrin 200mg (10 tablets/day)
Study: 16372588
Drug: ACEI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI treatment for 4 weeks or more pre-operatively
Study: 16372588
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ACEI treatment)
Study: 2130825
Drug: tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets containing Mg citrate/Mg lactate 5 mmol three times a day
Study: 2130825
Drug: tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets containing Mg citrate/Mg lactate and Mg hydroxide, 5 mmol three times a day
Study: 2130825
Drug: tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets containing Mg hydroxide (Emgesan 10.3 mmol) twice a day
Study: 2130825
Drug: solutions with
Normalized name: IV SOLUTIONS WITH ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: solutions with Mg chloride (0.5 mmol/ml) 10 ml three times a day
Study: 7000224
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids during or after operation (Wet)
Study: 7000224
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fluids (Dry)
Study: 31117236
Drug: Intracavernosal abobotulinumtoxinA
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intracavernosal abobotulinumtoxinA (Dysport®) 250 or 500 U as add-on therapy
Study: 21140269
Drug: Flavanol-rich cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-rich cocoa (918 mg)
Study: 17016059
Drug: Meloxicam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (7.5 mg cumulative dose)
Study: 15288981
Drug: Capsule polishing
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule polishing
Study: 2632753
Drug: Noradrenaline (subthreshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline (subthreshold doses)
Study: 30321318
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g force
Study: 30321318
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g force
Study: 26023212
Drug: lopinavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir monotherapy (arm A)
Study: 22128296
Drug: FSH (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH (starting dose 50 IU for up to three treatment cycles)
Study: 22128296
Drug: CC (50‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (50‐150 mg/day for 5 days)
Study: 17897270
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (preoxygenation with 100% oxygen alone)
Study: 11912385
Drug: Abarelix depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abarelix depot 100 mg
Study: 11912385
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 7.5 mg plus bicalutamide 50 mg daily
Study: 573763
Drug: Time-limited therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-limited therapy
Study: 573763
Drug: Time-unlimited therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-unlimited therapy
Study: 573763
Drug: Time-limited and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-limited and open-ended therapy (follow-up)
Study: 31891407
Drug: Tart cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart cherry juice concentrate (7.5 ml, 15 ml, 22.5 ml, or 30 ml twice daily for 28 days)
Study: 29235560
Drug: Milk (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (1.5 g fat/100 mL)
Study: 27686642
Drug: Fentanyl (0.001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.001 mg/kg)
Study: 27686642
Drug: Dezocine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine (0.1 mg/kg)
Study: 25424209
Drug: Diaper cream
Normalized name: CVS Zinc Oxide Diaper Cream
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaper cream applied twice daily (group II)
Study: 25424209
Drug: Wet wipes
Normalized name: ALCOHOL 0.75 TOPICAL CLOTH [WET WIPES]
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet wipes and diaper cream applied twice daily (group III)